Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Is This the Right Time to Rebalance Your Portfolio?

View original at nasdaq.com
Is This the Right Time to Rebalance Your Portfolio? Key Points Some investors think it’s prudent to prune their top stocks in a bull market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Everybody in the world is a long-term investor until the market goes down

    60% confidence

  • There is a little-known company called an 'Indispensable Monopoly' providing critical technology both Nvidia and Intel need

    60% confidence

  • Does not plan to prune top stocks anytime soon

    60% confidence

  • Believes in letting the winners ride instead of selling them too early for the sake of diversification

    60% confidence

  • AI could create the world's first trillionaire

    60% confidence

  • Has been invested in stocks for nearly two decades and has never regularly rebalanced portfolio

    60% confidence

  • Stock Advisor analyst team identified 10 best stocks for investors to buy now, and Nvidia was not one of them

    60% confidence

  • Amazon accounts for over 10% of his portfolio

    60% confidence

Data points we hold from this source

S&P 500 · total return199 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Is This the Right Time to Rebalance Your Portfolio? — Source | Via News | ViaNews EU